Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

33%

1 of 3 completed trials have results

Key Signals

1 recruiting1 with results

Enrollment Performance

Analytics

N/A

2(50.0%)

Phase 1

1(25.0%)

Phase 2

1(25.0%)

4Total

N/A(2)

Phase 1(1)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT04360941Phase 1Recruiting

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer

Role: collaborator

NCT03620643Phase 2Completed

Crizotinib in Lobular Breast, Diffuse Gastric and Triple Negative Lobular Breast Cancer or CDH1-mutated Solid Tumours

Role: collaborator

NCT04359420Not ApplicableCompleted

What Are the Benefits and Harms of Risk Stratified Screening in the NHS Breast Screening Programme: Study Protocol

Role: collaborator

NCT03818100Unknown

Neo-RT: A Study Investigating Whether Changing the Sequence of Treatments (Starting Radiotherapy Followed by Hormone Therapy Before Surgery) is Feasible

Role: collaborator

NCT04173897Not ApplicableCompleted

Living Better With Advanced Breast Cancer: Feasibility Evaluation of an Online Supportive Intervention.

Role: collaborator

NCT03468881Unknown

A Communication Skills Package to Prevent Fear of Cancer Recurrence

Role: collaborator

All 6 trials loaded